请输入您要查询的百科知识：

　

词条 McDonald criteria
释义

  1. Diagnostic Criteria

  2. Criticism

     Comparison of McDonald versions 

  3. 2010 Revisions

     Revised Diagnostic Criteria (2010) 

  4. 2017 revision

  5. Future directions

  6. References

{{Infobox diagnostic
| name = McDonald criteria
| image = File:Monthly multiple sclerosis anim cropped no text.gif|thumb|
| alt =
| caption = Animation showing dissemination of multiple sclerosis lesions in time and space as demonstrated by monthly MRI studies along a year
| pronounce =
| synonyms =
| reference_range =
| calculator =
| DiseasesDB =
| ICD10 =
| ICD9 =
| ICDO =
| MedlinePlus =
| eMedicine =
| MeshID =
| OPS301 =
| LOINC =
}}

The McDonald criteria are diagnostic criteria for multiple sclerosis (MS). These criteria are named after neurologist W. Ian McDonald who directed an international panel in association with the National Multiple Sclerosis Society (NMSS) of America and recommended revised diagnostic criteria for MS in April 2001. These new criteria intended to replace the Poser criteria and the older Schumacher criteria. They have undergone revisions in 2005,[1] 2010[2] and 2017.[3]

They maintain the Poser requirement to demonstrate "dissemination of lesions in space and time" (DIS and DIT)[2] but they discourage the previously used Poser terms such as "clinically definite" and "probable MS", and propose as diagnostic either "MS", "possible MS", or "not MS".[4]

The McDonald criteria maintained a scheme for diagnosing MS based solely on clinical grounds but also proposed for the first time that when clinical evidence is lacking, magnetic resonance imaging (MRI) findings can serve as surrogates for dissemination in space (DIS) and/or time (DIT) to diagnose MS.[5] The criteria try to prove the existence of demyelinating lesions, by image or by their effects, showing that they occur in different areas of the nervous system (DIS) and that they accumulate over time (DIT). The McDonald criteria facilitate the diagnosis of MS in patients who present with their first demyelinating attack and significantly increase the sensitivity for diagnosing MS without compromising the specificity.[5]

The McDonald criteria for the diagnosis of multiple sclerosis were revised first in 2005 to clarify exactly what is meant by an "attack", "dissemination" and a "positive MRI", etc.[1] Later they were revised again in 2017.[6]

McDonald criteria are the standard clinical case definition for MS and the 2010 version is regarded as the gold standard test for MS diagnosis.{{Citation needed|date=February 2012}}

Diagnostic Criteria

Clinical Presentation Additional Data Needed
* 2 or more attacks (relapses)
* 2 or more objective clinical lesions		 None; clinical evidence will suffice (additional evidence desirable but must be consistent with MS)
* 2 or more attacks
* 1 objective clinical lesion		 Dissemination in space, demonstrated by:
* MRI
* or a positive (cerebrospinal fluid) CSF and 2 or more MRI lesions consistent with MS
* or further clinical attack involving different site
* 1 attack
* 2 or more objective clinical lesions		Dissemination in time, demonstrated by:
* MRI
* or second clinical attack
* 1 attack
* 1 objective clinical lesion
(monosymptomatic presentation)		Dissemination in space demonstrated by:
* MRI
* or positive CSF and 2 or more MRI lesions consistent with MS
and
Dissemination in time demonstrated by:
* MRI
* or second clinical attack
Insidious neurological progression
suggestive of MS
(primary progressive MS)		One year of disease progression (retrospectively or prospectively determined) and

Two of the following:

a. Positive brain MRI (nine T2 lesions or four or more T2 lesions with positive VEP)

b. Positive spinal cord MRI (two focal T2 lesions)

c. Positive CSF

They discourage the previously used terms such as "clinically definite" and "probable MS", and propose as diagnostic either "MS", "possible MS", or "not MS".[4]

Criticism

Pathology is generally regarded as the gold standard in defining different forms of inflammatory demyelinating diseases.[7]

Specificity of the McDonald criteria is low due to the fact that the nature of the lesions is not considered, but only their dissemination. None of the criteria are MS-specific. In order to reduce false positives, McDonald et al. propose that their criteria should be applied only after any other disease has been ruled out.[4] In 2008 a consensus was developed for differential diagnosis.[8]

Another criticism of the McDonald criteria is that the definition of "lesions typical of MS" is unclear; a 2013 review identified the following characteristics: specific cell morphology shown by hematoxylin, demyelination shown by Luxol fast blue, macrophage appearance by KiM1P or CD68, damage to the axons shown by Bielschowsky stain, astrocytopathy shown by glial fibrillary acidic protein, and different lymphocyte subtypes, reacting to CD3, CD4, CD8, CD20 and CD138.[9]

The sensitivity of McDonald criteria is low with regard to pathologically defined MS because around 25% of MS cases are silent MS cases.[10]

McDonald criteria have been shown to have a low sensitivity and specificity (with respect to the pathological presence of lesions) in Asiatic populations.[11][12] They have good predictive quality (with respect to CIS [clinically isolated syndrome] to CDMS [Clinically Definite Multiple Sclerosis] conversion) when evaluated in non-selected populations.[13]

Comparison of McDonald versions

Currently there is not too much information comparing the sensibility and specificity of different McDonald versions against autopsy. Some reports have used Poser "CDMS" delayed diagnosis (during a two-year follow-up) as milestone to evaluate these parameters.

It seems that 2017 revision has higher sensitivity (85 vs. 30% and 85 vs. 41%) and lower specificity (33 vs. 63% and 63 vs. 85%) compared to the 2010 revisions and Poser CDMS,[14] at two years follow-up.

2010 Revisions

In 2010, the International Panel on Diagnosis of MS met in Dublin, Ireland for a third time to discuss and revise the McDonald diagnostic criteria.[2] Reasons for revisions to the criteria included the simplification of demonstration of CNS lesions in space and time via imaging, and to address criticisms that the previous criteria did not appropriately apply to Asian populations.[2]

One study has suggested that the new criteria allow a faster diagnosis, but with slight sacrifice in accuracy.[15]

Revised Diagnostic Criteria (2010)

Clinical Presentation Additional Data Needed
* 2 or more attacks (relapses)
* 2 or more objective clinical lesions		 None; clinical evidence will suffice (additional evidence desirable but must be consistent with MS)
* 2 or more attacks
* 1 objective clinical lesion		 Dissemination in space, demonstrated by:
* MRI
* or further clinical attack involving different site.
New criteria: Dissemination in Space (DIS) can be demonstrated by the presence of 1 or more T2 lesions in at least 2 of 4 of the following areas of the CNS: Periventricular, Juxtacortical, Infratentorial, or Spinal Cord.
* 1 attack
* 2 or more objective clinical lesions		Dissemination in time (DIT), demonstrated by:
* MRI
* or second clinical attack
New criteria: No longer a need to have separate MRIs run; Dissemination in time, demonstrated by: Simultaneous presence of asymptomatic gadolinium-enhancing

and nonenhancing lesions at any time; or A new T2 and/or gadolinium-enhancing lesion(s) on follow-up MRI, irrespective of its timing with reference to a baseline scan; or

Await a second clinical attack. [This allows for quicker diagnosis without sacrificing specificity, while improving sensitivity.]

* 1 attack
* 1 objective clinical lesion
(clinically isolated syndrome)		New criteria: Dissemination in space and time, demonstrated by:

For DIS:

1 or more T2 lesion in at least 2 of 4 MS-typical regions of the CNS

(periventricular, juxtacortical, infratentorial, or spinal cord); or

Await a second clinical attack implicating a different CNS site; and

For DIT:

Simultaneous presence of asymptomatic gadolinium-enhancing

and nonenhancing lesions at any time; or

A new T2 and/or gadolinium-enhancing lesion(s) on follow-up MRI,

irrespective of its timing with reference to a baseline scan; or

Await a second clinical attack.

Insidious neurological progression
suggestive of MS
(primary progressive MS)		New criteria: One year of disease progression (retrospectively or prospectively determined) and

two or three of the following:

1. Evidence for DIS in the brain based on 1 or more T2 lesions in the

MS-characteristic (periventricular, juxtacortical, or infratentorial) regions

2. Evidence for DIS in the spinal cord based on 2 or more T2

lesions in the cord

3. Positive CSF (isoelectric focusing evidence of oligoclonal bands

and/or elevated IgG index)

2017 revision

The last revision (as of 2018) is the 2017 revision[6]. It has been reported to improve sensibility up to an 82% (respect around 8 years CIS to MS conversion, retrospectively evaluated). The 2017 revision predicted 86.8% of positives in the follow up using as reference the 2010 criteria after a follow-up of 3.8 ± 2.9 years[16]. No reduction in specificity was reported.

The 2017 revision tries to accelerate the diagnosis without risking specificity. The new recommendations include[6]:

  • First of all, probably the most polemical change, a patient with CIS (only one demyelinating lesion) can now be diagnosed as MS if a MRI shows dissemination in space (DIS). In these cases dissemination in time (DIT) can be substituted by a laboratory testing of oligoclonal bands.
  • Second, both symptomatic and asymptomatic lesions can be considered for showing DIS and DIT
  • Third, also cortical lesions can be used to show DIS.
  • Fourth, also for PPMS cortical and asymptomatic lesions can be used in diagnosis.

Future directions

Improvements in Imaging technology:

The European group MAGNIMS periodically publishes guidelines for using MRI in the diagnosis of MS that are updated as MRI technology evolves.[17]{{third party inline|date=May 2016}} Moreover, new MRI techniques, such as double inversion recovery imaging or phase sensitive inversion recovery, can be used to identify more lesions in MS which, if further validated, could be included in future criteria. Another promising MRI technique is magnetic transfer imaging, which will allow the detection of damage in normal-appearing brain tissue away from focal lesions. Finally, high resolution spectral domain optical coherence tomography could prove to be a very promising and sensitive way of identifying optic neuritis in the future.[5]

Improvements in Biomarkers:

Four biomarkers were identified for further study by the 2010 revisions of McDonald Criteria: The CSF,[18] the serum anti-GAGA4[19] and protein signatures[20] and finally the circulating microRNA[21] Some blood tests have been proposed based in circulating neurofilament light chain (NFL), in RNA profiling[22] or in the MRZ reaction.

In the 2017 revision, for the first time, a laboratory test (CSF oligoclonal bands) was introduced in diagnosis.

Addressing subclinical disease:

Another issue of great clinical significance that is not addressed by 2010 McDonald criteria is subclinical disease. There are some patients who were incidentally found to have brain lesions with appearance and location consistent with MS who are now classified as having a radiologically isolated syndrome (RIS). Some of these people will develop MS even after several years. Because early initiation of MS disease-modifying therapy is associated with better clinical outcomes, it is important to identify individuals in the subclinical stage of disease and determine if initiation of treatment at this stage is beneficial. More research is currently being conducted to clarify this issue and address which RIS patients will progress to definite MS. Depending on the findings of this research, future criteria might address this controversial but highly important issue of MS care.[5]

References

1. ^1 {{cite journal |doi=10.1002/ana.20703 |pmid=16283615 |title=Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria' |journal=Annals of Neurology |volume=58 |issue=6 |pages=840–6 |year=2005 |last1=Polman |first1=Chris H |last2=Reingold |first2=Stephen C |last3=Edan |first3=Gilles |last4=Filippi |first4=Massimo |last5=Hartung |first5=Hans-Peter |last6=Kappos |first6=Ludwig |last7=Lublin |first7=Fred D |author-link7=Fred D. Lublin|last8=Metz |first8=Luanne M |last9=McFarland |first9=Henry F |last10=O'Connor |first10=Paul W |last11=Sandberg-Wollheim |first11=Magnhild |last12=Thompson |first12=Alan J |last13=Weinshenker |first13=Brian G |last14=Wolinsky |first14=Jerry S | author-link14=Jerry Wolinsky|citeseerx=10.1.1.604.2677 }}
2. ^1 2 3 {{cite journal |doi=10.1002/ana.22366 |pmid=21387374 |pmc=3084507 |title=Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria |journal=Annals of Neurology |volume=69 |issue=2 |pages=292–302 |year=2011 |last1=Polman |first1=Chris H |last2=Reingold |first2=Stephen C |last3=Banwell |first3=Brenda |last4=Clanet |first4=Michel |last5=Cohen |first5=Jeffrey A |last6=Filippi |first6=Massimo |last7=Fujihara |first7=Kazuo |last8=Havrdova |first8=Eva |last9=Hutchinson |first9=Michael |last10=Kappos |first10=Ludwig |last11=Lublin |first11=Fred D |last12=Montalban |first12=Xavier |last13=O'Connor |first13=Paul |last14=Sandberg-Wollheim |first14=Magnhild |last15=Thompson |first15=Alan J |last16=Waubant |first16=Emmanuelle |last17=Weinshenker |first17=Brian |last18=Wolinsky |first18=Jerry S }}
3. ^{{cite journal |doi=10.1016/S1474-4422(17)30470-2 |pmid=29275977 |title=Diagnosis of multiple sclerosis: 2017 revisions of the Mc Donald criteria |journal=The Lancet Neurology |volume=17 |issue=2 |pages=162–173 |year=2018 |last1=Thompson |first1=Alan J |last2=Banwell |first2=Brenda L |last3=Barkhof |first3=Frederik |last4=Carroll |first4=William M |last5=Coetzee |first5=Timothy |last6=Comi |first6=Giancarlo |last7=Correale |first7=Jorge |last8=Fazekas |first8=Franz |last9=Filippi |first9=Massimo |last10=Freedman |first10=Mark S |last11=Fujihara |first11=Kazuo |last12=Galetta |first12=Steven L |last13=Hartung |first13=Hans Peter |last14=Kappos |first14=Ludwig |last15=Lublin |first15=Fred D |last16=Marrie |first16=Ruth Ann |last17=Miller |first17=Aaron E |last18=Miller |first18=David H |last19=Montalban |first19=Xavier |last20=Mowry |first20=Ellen M |last21=Sorensen |first21=Per Soelberg |last22=Tintoré |first22=Mar |last23=Traboulsee |first23=Anthony L |last24=Trojano |first24=Maria |last25=Uitdehaag |first25=Bernard M J |last26=Vukusic |first26=Sandra |last27=Waubant |first27=Emmanuelle |last28=Weinshenker |first28=Brian G |last29=Reingold |first29=Stephen C |last30=Cohen |first30=Jeffrey A |url=http://discovery.ucl.ac.uk/10041020/1/Barkhof_Diagnostic%20criteria_revision%201_final_10OCT2017.pdf }}
4. ^1 2 {{cite journal |doi=10.1002/ana.1032 |pmid=11456302 |title=Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis |journal=Annals of Neurology |volume=50 |issue=1 |pages=121–7 |year=2001 |last1=McDonald |first1=W. Ian |last2=Compston |first2=Alistair |last3=Edan |first3=Gilles |last4=Goodkin |first4=Donald |last5=Hartung |first5=Hans-Peter |last6=Lublin |first6=Fred D |last7=McFarland |first7=Henry F |last8=Paty |first8=Donald W |last9=Polman |first9=Chris H |last10=Reingold |first10=Stephen C |last11=Sandberg-Wollheim |first11=Magnhild |last12=Sibley |first12=William |last13=Thompson |first13=Alan |last14=Van Den Noort |first14=Stanley |last15=Weinshenker |first15=Brian Y |last16=Wolinsky |first16=Jerry S |citeseerx=10.1.1.466.5368 }}
5. ^1 2 3 {{cite journal |doi=10.1007/s11910-016-0688-8 |pmid=27549391 |title=Diagnostic Criteria, Classification and Treatment Goals in Multiple Sclerosis: The Chronicles of Time and Space |journal=Current Neurology and Neuroscience Reports |volume=16 |issue=10 |pages=90 |year=2016 |last1=Ntranos |first1=Achilles |last2=Lublin |first2=Fred }}
6. ^1 2 {{cite journal |doi=10.1016/S1474-4422(17)30470-2 |pmid=29275977 |title=Diagnosis of multiple sclerosis: 2017 revisions of the Mc Donald criteria |journal=The Lancet Neurology |volume=17 |issue=2 |pages=162–173 |year=2018 |last1=Thompson |first1=Alan J |last2=Banwell |first2=Brenda L |last3=Barkhof |first3=Frederik |last4=Carroll |first4=William M |last5=Coetzee |first5=Timothy |last6=Comi |first6=Giancarlo |last7=Correale |first7=Jorge |last8=Fazekas |first8=Franz |last9=Filippi |first9=Massimo |last10=Freedman |first10=Mark S |last11=Fujihara |first11=Kazuo |last12=Galetta |first12=Steven L |last13=Hartung |first13=Hans Peter |last14=Kappos |first14=Ludwig |last15=Lublin |first15=Fred D |last16=Marrie |first16=Ruth Ann |last17=Miller |first17=Aaron E |last18=Miller |first18=David H |last19=Montalban |first19=Xavier |last20=Mowry |first20=Ellen M |last21=Sorensen |first21=Per Soelberg |last22=Tintoré |first22=Mar |last23=Traboulsee |first23=Anthony L |last24=Trojano |first24=Maria |last25=Uitdehaag |first25=Bernard M J |last26=Vukusic |first26=Sandra |last27=Waubant |first27=Emmanuelle |last28=Weinshenker |first28=Brian G |last29=Reingold |first29=Stephen C |last30=Cohen |first30=Jeffrey A |url=http://discovery.ucl.ac.uk/10041020/1/Barkhof_Diagnostic%20criteria_revision%201_final_10OCT2017.pdf }}
7. ^{{cite journal | author = Lassmann Hans | year = 2010 | title = Acute disseminated encephalomyelitis and multiple sclerosis | url = | journal = Brain | volume = 133| issue = Pt 2| pages = 317–319| doi = 10.1093/brain/awp342 | pmid=20129937}}
8. ^{{cite journal |vauthors=Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, Galetta SL, Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban X, Panitch H, Richert JR, Reingold SC, Polman CH | year = 2008 | title = Differential diagnosis of suspected multiple sclerosis: a consensus approach | journal = Mult Scler | volume = 14 | issue = 9| pages = 1157–1174 | doi = 10.1177/1352458508096878 | pmid=18805839 | pmc=2850590}}
9. ^{{cite journal |doi=10.1212/01.CON.0000433291.23091.65 |pmid=23917093 |pmc=3915566 |title=Pathology of Multiple Sclerosis |journal=CONTINUUM: Lifelong Learning in Neurology |volume=19 |issue=4 Multiple Sclerosis |pages=901–21 |year=2013 |last1=Popescu |first1=Bogdan F. Gh |last2=Pirko |first2=Istvan |last3=Lucchinetti |first3=Claudia F }}
10. ^{{cite journal | author = Engell T | date = May 1989 | title = A clinical patho-anatomical study of clinically silent multiple sclerosis | url = | journal = Acta Neurol Scand | volume = 79 | issue = 5| pages = 428–30 | doi=10.1111/j.1600-0404.1989.tb03811.x | pmid=2741673}}
11. ^HT Chong et al (2006) Proposed modifications to McDonald diagnostic criteria for Asians with multiple sclerosis, Neurology Asia 11:87–90
12. ^{{cite journal|last1=Chong|first1=H|last2=Kira|first2=J|last3=Tsai|first3=C|last4=Ong|first4=B|last5=Li|first5=P|last6=Kermode|first6=A|last7=Tan|first7=C|title=Proposed modifications to the McDonald criteria for use in Asia|journal=Multiple Sclerosis|date=19 June 2009|volume=15|issue=7|pages=887–888|doi=10.1177/1352458509104587|pmid=19542266}}
13. ^{{cite journal|last1=Fortini|first1=Alexandre S.|last2=Sanders|first2=Elizabeth L.|last3=Weinshenker|first3=Brian G.|last4=Katzmann|first4=Jerry A.|title=Cerebrospinal Fluid Oligoclonal Bands in the Diagnosis of Multiple Sclerosis Isoelectric Focusing With IgG Immunoblotting Compared With High-Resolution Agarose Gel Electrophoresis and Cerebrospinal Fluid IgG Index|journal=American Journal of Clinical Pathology|date=1 November 2003|volume=120|issue=5|pages=672–675|doi=10.1309/Y5VFF2UAW0RK5W63|pmid=14608891}}
14. ^Habek M et al, Establishing the diagnosis of multiple sclerosis in Croatian patients with clinically isolated syndrome: 2010 versus 2017 McDonald criteria, Mult Scler Relat Disord. 2018 Jul 20;25:99-103. doi: 10.1016/j.msard.2018.07.035
15. ^{{cite journal|last1=Runia|first1=TF|last2=Jafari|first2=N|last3=Hintzen|first3=RQ|title=Application of the 2010 revised criteria for the diagnosis of multiple sclerosis to patients with clinically isolated syndromes.|journal=European Journal of Neurology|date=December 2013|volume=20|issue=12|pages=1510–6|doi=10.1111/ene.12243|pmid=23906114}}
16. ^Gaetani L, Prosperini L, Mancini A, Eusebi P, Cerri MC, Pozzilli C, Calabresi P, Sarchielli P, Di Filippo M., 2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes. J Neurol. 2018 Sep 8. doi: 10.1007/s00415-018-9048-8.
17. ^{{cite journal |doi=10.1016/S1474-4422(15)00393-2 |pmid=26822746 |pmc=4760851 |title=MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines |journal=The Lancet Neurology |volume=15 |issue=3 |pages=292–303 |year=2016 |last1=Filippi |first1=Massimo |last2=Rocca |first2=Maria A |last3=Ciccarelli |first3=Olga |last4=De Stefano |first4=Nicola |last5=Evangelou |first5=Nikos |last6=Kappos |first6=Ludwig |last7=Rovira |first7=Alex |last8=Sastre-Garriga |first8=Jaume |last9=Tintorè |first9=Mar |last10=Frederiksen |first10=Jette L |last11=Gasperini |first11=Claudio |last12=Palace |first12=Jacqueline |last13=Reich |first13=Daniel S |last14=Banwell |first14=Brenda |last15=Montalban |first15=Xavier |last16=Barkhof |first16=Frederik }}
18. ^{{cite journal |doi=10.1016/j.jneuroim.2009.09.002 |pmid=19782408 |title=Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis |journal=Journal of Neuroimmunology |volume=219 |issue=1–2 |pages=1–7 |year=2010 |last1=Awad |first1=Amer |last2=Hemmer |first2=Bernhard |last3=Hartung |first3=Hans-Peter |last4=Kieseier |first4=Bernd |last5=Bennett |first5=Jeffrey L |last6=Stuve |first6=Olaf }}
19. ^{{cite journal |doi=10.1016/j.jneuroim.2009.07.017 |pmid=19879655 |title=Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases |journal=Journal of Neuroimmunology |volume=217 |issue=1–2 |pages=95–101 |year=2009 |last1=Brettschneider |first1=Johannes |last2=Jaskowski |first2=Troy D |last3=Tumani |first3=Hayrettin |last4=Abdul |first4=Sana |last5=Husebye |first5=Dee |last6=Seraj |first6=Haniah |last7=Hill |first7=Harry R |last8=Fire |first8=Ella |last9=Spector |first9=Larissa |last10=Yarden |first10=Jennifer |last11=Dotan |first11=Nir |last12=Rose |first12=John W }}
20. ^{{cite journal |vauthors=Quintana FJ, Farez MF, Viglietta V, etal | year = 2008 | title = Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis | journal = Proc Natl Acad Sci U S A | volume = 105 | issue = 48| pages = 18889–18894 | doi=10.1073/pnas.0806310105 | pmid=19028871 | pmc=2596207}}
21. ^{{cite journal |vauthors=Keller A, Leidinger P, Lange J, etal | year = 2009 | title = Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls | journal = PLOS One | volume = 4 | issue = 10| page = e7440 | doi=10.1371/journal.pone.0007440 | pmid=19823682 | pmc=2757919}}
22. ^Nickles D et al., Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls, Hum Mol Genet. 2013 Oct 15;22(20):4194-205. doi: 10.1093/hmg/ddt267. Epub 2013 Jun 6.
{{Multiple sclerosis}}{{Diseases of the nervous system}}{{Use dmy dates|date=April 2017}}

4 : Neurology|Autoimmune diseases|Neurological disorders|Multiple sclerosis
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/11/17 9:08:27